Skepta and PUMA Launch Groundbreaking Collection 
Converse Faces Job Cuts as Nike Aims for $2 Billion in Cost Savings 
Green industry yes, conservation no: a budget for people, not for nature 
Coca-Cola Launches Data-Driven Insights Platform for Retail and Foodservice Industries 
ECB Calls for Monitoring and Possible Regulation of AI in Finance 
Why banks consider renewable energy to be a riskier investment than fossil fuels 
Dolly Parton Serves Up Sweetness with Krispy Kreme Collaboration 
McDonald's Faces Backlash Over $5 Meal Deal: Customers Call It 'Skimpy' 
Semaglutide's Benefits Beyond Weight Loss: New Insights from the SELECT Trial 
How supermarkets are changing their branding to make you think they’re cheaper 
McDonald’s Rolls Out $5 Meal Deals to Emphasize Affordability Amid Rising Costs 
Nike vs. Adidas: Anthony Edwards’ and Wembanyama’s Sneakers Soar in Popularity 
PUMA Welcomes AC Milan Star Theo Hernández to the Family 
McDonald's China Faces Backlash for Food Hygiene Violations 
NEW YORK, Dec. 03, 2015 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Valeant Pharmaceuticals International, Inc. (“Valeant Pharmaceuticals”) (NYSE:VRX) between February 23, 2015 and October 20, 2015.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. To get more information go to:
http://zlk.9nl.com/valeant-pharmaceuticals
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that during the Class Period, defendants made false and misleading statements and/or failed to disclose adverse information about the Company’s business and prospects, including that: (a) the Company was using a network of specialty mail-order pharmacies that it actually controlled to prop up sales of its high-priced drugs and to keep patients and their insurance companies from switching to less costly generic drugs; (b) that Valeant's undisclosed use of specialty pharmacies left it subject to increased regulatory risks; and (c) that without the use of the specialty pharmacies, Valeant’s financial performance and Class Period financial guidance would have been negatively impacted. As a result of these false and misleading statements and/or omissions, Valeant stock traded at artificially inflated prices during the Class Period, reaching over $260 per share.
If you suffered a loss in Valeant Pharmaceuticals you have until December 21, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
